GlobeNewswire
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
📈
AI Sentiment
Highly Positive
8/10
Biofrontera Inc. News
Latest updates and market news for BFRI
2 news
Feb 8 - Feb 14, 2026
Page 1
GlobeNewswire
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
📈
AI Sentiment
Highly Positive
9/10
Share this news page